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Dr Colleen Johnson (Springfield, Ill). I have two questions
for you. Can you better define multilevel disease and whether that
was a predominance of aortoiliac disease or femoropopliteal dis-
ease, as those behave a little differently postintervention. Secondly,
in themanuscript youmention that your length of hospital stay was
6.2 days, plus or minus 9 days. Most of us would consider percu-
taneous interventions to be a 1?day procedure, and I am a little
curious as to what the protocol or treatment paradigms were that
surrounded those longer hospital stays.
Dr Mikel Sadek. In this study, the levels of vascular disease
were divided into three categories: (1) the tibial or infrapopliteal
vasculature, (2) the femoropopliteal vasculature, and (3) the aor-
toiliac vasculature. Single-level disease referred specifically to iso-
lated disease of the infrapopliteal vasculature. Multilevel disease
involved the infrapopliteal vasculature, as well as at least one
additional level.
With regards to the length of hospital stay, patients were
included in this study who were not in the hospital initially for
treatment of their lower extremity peripheral arterial disease.
Therefore, other medical issues frequently kept patients in the
hospital beyond the typical postprocedural course for recovery.
Dr Anil Hingorani (Brooklyn, NY). I just wanted to ask
about your patency rates in terms of how did you obtain patency
rates? Did you just do duplexes of all the infrapopliteal arteries thatDr Sadek. Patency rates were obtained postprocedurally us-
ing a combination of ABI/PVR [ankle-brachial index/pulse vol-
ume recording] and duplex studies.
Dr Hingorani. So do you routinely get duplex studies of the
infrapopliteal vessels on these types of patients?
Dr Sadek. Postprocedural follow?up was left to the discretion
of the investigator. That said, the majority of investigators rou-
tinely obtain ABI/PVR and duplex studies postprocedurally.
Dr Victor Bernhard (Chicago, Ill). I am somewhat confused
as to why the multilevel patients did better than the single?level
patients, unless I missed your stratification of how much tibial
disease was present in one group vs the other. Maybe you could
clarify that.
Dr Sadek. The severity of tibial disease may be the reason why
patients who underwent multilevel intervention exhibited im-
proved outcomes as compared to patients who underwent single-
level intervention. Additional analysis might clarify whether in-
creased distal disease burden affected outcomes.
Dr Bernhard. In other words, you haven’t stratified them
according to the degree of tibial disease?
Dr Sadek.Correct.
Dr Hasan Dosluoglu (Buffalo, NY). The limb salvage was
somewhat lower at 18 months, or 68%, if I got it correctly. Was
limb salvage rate different between diabetics and nondiabetics in
this series? Ironically the patients with one?level disease that you
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ones who did worse. So does that really mean that when you have
a somewhat acceptable looking SFA [superficial femoral artery],
little ragged and with diffuse disease, maybe, ironically, should be
the ones that we should more aggressively consider bypasses,
because that one?level correction of the most significant stenosis
may not be enough. Maybe that is what your study is actually
telling us. What do you think?
Dr Sadek.With regards to your first question and diabetes, we
did not note a difference in limb salvage between diabetics and
non-diabetics. And with regards to your second question, I think
you make a valid point.
Dr Peter Schubart (San Jose, Calif). I wanted to commend
you on your series and to note that you did have 10%more diabetic
patients in the tibial vessel disease, which I think would tend to add
to the trend of failure. I wondered whether, in looking at your
patency data, whether in the multilevel disease you discriminated
between failure in the proximal segment and failure in the tibials?
In other words, was the tibial failure equivalent between the two
groups?Dr Sadek. For multilevel interventions, whenever there was a
failure anywhere along the vascular tree that required reinterven-
tion, that affected the patency.
Dr Schubart. It might be interesting to analyze the data by
infrapopliteal vs above the knee in terms of trying to see if you are
treating apples and apples.
Dr Sadek. Absolutely. You make an excellent suggestion.
Dr Manju Kalra (Rochester, Minn). I too am intrigued by
your results of multilevel vs single-level treatment. In patients with
multilevel treatment, did you set out primarily to treat the femo-
ropopliteal segment or the tibial segment? It would also be inter-
esting to know the extent of disease and TASC [TransAtlantic
InterSociety Consensus] classification of the femoropopliteal seg-
ments treated in order to assess their relative significance and
contribution to clinical improvement following intervention.
Dr Sadek. With regards to multilevel disease, which came
first, the chicken or the egg? This was a retrospective review of a
prospectively maintained database; therefore, I cannot make a
comment at this time regarding the intention for treatment. And
with regards to TASC classification for the femoropopliteal lesions,
that is an excellent suggestion for improving the manuscript.
